keyword
MENU ▼
Read by QxMD icon Read
search

ketamine depression

keyword
https://www.readbyqxmd.com/read/28441895/ketamine-s-dose-related-effects-on-anxiety-symptoms-in-patients-with-treatment-refractory-anxiety-disorders
#1
Paul Glue, Natalie J Medlicott, Sarah Harland, Shona Neehoff, Bridie Anderson-Fahey, Martin Le Nedelec, Andrew Gray, Neil McNaughton
The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of ketamine in 12 patients with refractory generalized anxiety disorder and/or social anxiety disorder who were not currently depressed, using an ascending single dose study design (0...
April 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28424861/s-ketamine-compared-to-etomidate-during-electroconvulsive-therapy-in-major-depression
#2
Maxim Zavorotnyy, Ina Kluge, Kathrin Ahrens, Thomas Wohltmann, Benjamin Köhnlein, Patricia Dietsche, Udo Dannlowski, Tilo Kircher, Carsten Konrad
Objective of the study was to compare two commonly used anesthetic drugs, S-ketamine and etomidate, regarding their influence on seizure characteristics, safety aspects, and outcome of electroconvulsive therapy (ECT) in major depression. Treatment data of 60 patients who underwent a total number of 13 ECTs (median) because of the severe or treatment-resistant major depressive disorder (DSM-IV) were analyzed. Etomidate, mean dosage (SD) = 0.25 (0.04) mg/kg, was used for anesthesia in 29 participants; 31 patients received S-ketamine, mean dosage (SD) = 0...
April 19, 2017: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/28422805/a-randomized-pilot-study-comparing-ketamine-and-methohexital-anesthesia-for-electroconvulsive-therapy-in-patients-with-depression
#3
Shona L Ray-Griffith, Lou Ann Eads, Xiaotong Han, Kimberly Golden, Zachary N Stowe
OBJECTIVE: This randomized controlled pilot study examines the differences in response to electroconvulsive therapy (ECT) as defined by an improvement of depressive symptoms between ketamine and methohexital as the primary anesthetic agent. Adverse effects and cognitive tolerability were also examined. METHODS: Subjects undergoing ECT for unipolar or bipolar depression were randomized to receive ketamine or methohexital as the anesthetic agent. Primary outcome measure includes the Hamilton rating scale for depression (17-item)...
April 18, 2017: Journal of ECT
https://www.readbyqxmd.com/read/28419244/resolvin-d1-and-d2-reverse-lipopolysaccharide-induced-depression-like-behaviors-through-the-mtorc1-signaling-pathway
#4
Satoshi Deyama, Yuka Ishikawa, Kotomi Yoshikawa, Kento Shimoda, Soichiro Ide, Masamichi Satoh, Masabumi Minami
Background: Resolvin D1 (RvD1) and D2 (RvD2) are bioactive lipid mediators that are generated from docosahexaenoic acid (DHA). Although recent preclinical studies suggest that these compounds have antidepressant effects, their mechanisms of action remain unclear. Methods: We investigated mechanisms underlying the antidepressant effects of RvD1 and RvD2 in lipopolysaccharide (LPS; 0.8 mg/kg, i.p.)-induced depression model mice using a tail suspension test. Results: Intracerebroventricular (i...
April 13, 2017: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28418641/classics-in-chemical-neuroscience-ketamine
#5
Marshall W Tyler, Harmony B Yourish, Dawn F Ionescu, Stephen J Haggarty
Ketamine, a molecule of many faces, has contributed immeasurably to numerous realms of clinical practice and scientific inquiry. From anesthesia and analgesia to depression and schizophrenia, it continues to shed light on the molecular underpinnings of pain, consciousness, and the pathophysiology of neuropsychiatric disorders. In particular, research on ketamine's mechanism of action is providing new hope in the search for therapies for treatment-resistant depression and affords insights into disorders of glutamatergic dysfunction...
April 21, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28415832/the-synergistic-effect-of-dual-use-of-amphetamine-type-stimulants-and-ketamine-on-drug-induced-psychotic-symptoms-in-chinese-synthetic-drug-users
#6
Xue-Bing Liu, Yao Zhang, Xu-Yi Wang, Wei Hao
The use of amphetamine-type stimulants (ATS) and ketamine is of particular clinical concern because of its associated psychotic symptoms. In Chinese clinical practice, ATS and ketamine are commonly used simultaneously, but very few studies have reported the symptom profile of users who use both drugs. This study determined whether the combined use of ATS and ketamine is associated with more psychotic symptoms than either ATS or ketamine alone. According to drug use characteristics, 375 Chinese synthetic drug users were categorized into 2 pairs of comparison groups: ATS-only (n=125) vs...
March 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28413097/mglu2-3-receptor-antagonists-as-novel-antidepressants
#7
REVIEW
Shigeyuki Chaki
Based on the discovery of the robust antidepressant effects of ketamine in patients with depression, including those with treatment-resistant depression, agents acting on the glutamatergic system have drawn much attention as potential novel antidepressants. Among the agents acting on the glutamatergic system, preclinical data have indicated that the group II metabotropic glutamate (mGlu) receptors, mGlu2 and mGlu3, are attractive targets for the development of novel antidepressants. The antidepressant effects of mGlu2/3 receptor antagonists have been demonstrated in rodent models, and the synaptic and neural mechanisms underlying the antidepressant effects of these compounds have been investigated...
April 13, 2017: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/28408985/new-drugs-in-psychiatry-focus-on-new-pharmacological-targets
#8
REVIEW
Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, Filippo Drago
The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer's disease...
2017: F1000Research
https://www.readbyqxmd.com/read/28408831/modulation-of-the-activity-of-n-methyl-d-aspartate-receptors-as-a-novel-treatment-option-for-depression-current-clinical-evidence-and-therapeutic-potential-of-rapastinel-glyx-13
#9
REVIEW
Andrei-Nicolae Vasilescu, Nina Schweinfurth, Stefan Borgwardt, Peter Gass, Undine E Lang, Dragos Inta, Sarah Eckart
Classical monoaminergic antidepressants show several disadvantages, such as protracted onset of therapeutic action. Conversely, the fast and sustained antidepressant effect of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine raises vast interest in understanding the role of the glutamate system in mood disorders. Indeed, numerous data support the existence of glutamatergic dysfunction in major depressive disorder (MDD). Drawback to this short-latency therapy is its side effect profile, especially the psychotomimetic action, which seriously hampers the common and widespread clinical use of ketamine...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28407315/drugs-with-antidepressant-properties-affect-tryptophan-metabolites-differently-in-rodent-models-with-depression-like-behavior
#10
Amanda Eskelund, Yan Li, David P Budac, Heidi K Müller, Gulinello Maria, Connie Sanchez, Gregers Wegener
The metabolism of tryptophan through kynurenine and serotonin pathways is linked to depression. Here, effects of different drugs with antidepressant properties (vortioxetine, fluoxetine and ketamine) on various tryptophan metabolites in different brain regions and plasma were examined using tandem mass spectrometry (LC-MS/MS), in Flinders Sensitive Line (FSL) rats, a genetic rat model of depression, and its controls: Flinders Resistant Line (FRL) and Sprague-Dawley (SD) rats. Protein levels of kynurenine pathway enzymes were measured in the brains and livers of these rat strains...
April 13, 2017: Journal of Neurochemistry
https://www.readbyqxmd.com/read/28397841/ketamine-induced-reduction-in-mglur5-availability-is-associated-with-an-antidepressant-response-an-11-c-abp688-and-pet-imaging-study-in-depression
#11
I Esterlis, N DellaGioia, R H Pietrzak, D Matuskey, N Nabulsi, C G Abdallah, J Yang, C Pittenger, G Sanacora, J H Krystal, R V Parsey, R E Carson, C DeLorenzo
The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-aspartate glutamate receptor antagonist, have not been fully elucidated. This study examined the effects of ketamine on ligand binding to a metabotropic glutamatergic receptor (mGluR5) in individuals with major depressive disorder (MDD) and healthy controls. Thirteen healthy and 13 MDD nonsmokers participated in two [(11)C]ABP688 positron emission tomography (PET) scans on the same day-before and during intravenous ketamine administration-and a third scan 1 day later...
April 11, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28395988/ketamine-treatment-for-depression-opportunities-for-clinical-innovation-and-ethical-foresight
#12
REVIEW
Ilina Singh, Celia Morgan, Valerie Curran, David Nutt, Anne Schlag, Rupert McShane
We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The analysis of ethical considerations is contextualised in an overview of the evidence for ketamine use in depression, and a review of the drug's safety profile. We find that, based on current evidence, ketamine use for severe, treatment-resistant depression does not violate ethical principles; however, clinicians and professional bodies must take steps to ensure that guidelines for good practice are enacted, that all experimental and trial data are made available through national registries, and that the risk potential of ketamine treatment continues to be monitored and modelled...
April 5, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28395987/the-practicalities-and-ethics-of-ketamine-for-depression
#13
Christopher James Ryan, Colleen Loo
No abstract text is available yet for this article.
April 5, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28395871/a-circadian-genomic-signature-common-to-ketamine-and-sleep-deprivation-in-the-anterior-cingulate-cortex
#14
Ricardo Orozco-Solis, Emilie Montellier, Lorena Aguilar-Arnal, Shogo Sato, Marquis P Vawter, Blynn G Bunney, William E Bunney, Paolo Sassone-Corsi
BACKGROUND: Conventional antidepressants usually require several weeks to achieve a full clinical response in patients with major depressive disorder, an illness associated with dysregulated circadian rhythms and a high incidence of suicidality. Two rapid-acting antidepressant strategies, low-dose ketamine (KT) and sleep deprivation (SD) therapies, dramatically reduce depressive symptoms within 24 hours in a subset of major depressive disorder patients. However, it is unknown whether they exert their actions through shared regulatory mechanisms...
March 1, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/28392760/accelerated-recovery-of-consciousness-after-general-anesthesia-is-associated-with-increased-functional-brain-connectivity-in-the-high-gamma-bandwidth
#15
Duan Li, Viviane S Hambrecht-Wiedbusch, George A Mashour
Recent data from our laboratory demonstrate that high-frequency gamma connectivity across the cortex is present during consciousness and depressed during unconsciousness. However, these data were derived from static and well-defined states of arousal rather than during transitions that would suggest functional relevance. We also recently found that subanesthetic ketamine administered during isoflurane anesthesia accelerates recovery upon discontinuation of the primary anesthetic and increases gamma power during emergence...
2017: Frontiers in Systems Neuroscience
https://www.readbyqxmd.com/read/28386522/ketamine-therapy-for-treatment-resistant-depression-in-a-patient-with-multiple-sclerosis-a-case-report
#16
Michael M Messer, Irina V Haller
Objective: Depression is a common condition among patients with multiple sclerosis and often becomes resistant to oral antidepressants. We report a patient with multiple sclerosis who developed severe treatment-resistant depression and who was successfully treated with intravenous ketamine over the period of two years. Methods: Ketamine treatment protocol included an initial series of six treatments administered every other day, followed by a maintenance schedule. Ketamine was administered intravenously at 0...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28385704/adjunctive-ketamine-in-electroconvulsive-therapy-updated-systematic-review-and-meta-analysis
#17
REVIEW
Alexander McGirr, Marcelo T Berlim, David J Bond, Peter Y Chan, Lakshmi N Yatham, Raymond W Lam
BackgroundKetamine has emerged as a novel therapeutic agent for major depressive episodes, spurring interest in its potential to augment electroconvulsive therapy (ECT).AimsWe sought to update our preliminary systematic review and meta-analysis, focusing on randomised controlled trials (RCTs) involving an index course of ECT, and testing the hypothesis that lack of efficacy is due to barbiturate anaesthetic co-administration.MethodWe searched EMBASE, CENTRAL and Medline to identify RCTs examining the efficacy of ketamine during a course of ECT...
April 6, 2017: British Journal of Psychiatry: the Journal of Mental Science
https://www.readbyqxmd.com/read/28372596/a-proof-of-concept-investigation-into-ketamine-as-a-pharmacological-treatment-for-alcohol-dependence-study-protocol-for-a-randomised-controlled-trial
#18
Amy McAndrew, Will Lawn, Tobias Stevens, Lilla Porffy, Brigitta Brandner, Celia J A Morgan
BACKGROUND: Worldwide, alcohol abuse is a burgeoning problem. Abstinence is key to allow recovery of physical and mental health as well as quality of life, but treatment for alcohol dependence is associated with high relapse rates. Preliminary data have suggested that a combined repeated ketamine and psychological therapy programme may be effective in reducing relapse in severe alcohol use disorder. This non-commercial proof-of-concept trial is aimed at making a preliminary assessment of the effectiveness of this combined treatment in this patient group...
April 4, 2017: Trials
https://www.readbyqxmd.com/read/28363076/continuous-intravenous-infusion-anesthesia-with-medetomidine-ketamine-and-midazolam-after-induction-with-a-combination-of-etorphine-medetomidine-and-midazolam-or-with-medetomidine-ketamine-and-butorphanol-in-impala-aepyceros-melampus
#19
Christina A Gerlach, Maya S Kummrow, Leith C Meyer, Gareth E Zeiler, George F Stegmann, Roxanne K Buck, Geoffrey T Fosgate, Sabine B Kästner
In order to develop a long-term anesthesia for flighty antelope species in field situations, two different protocols for induction and maintenance with an intravenous infusion were evaluated in wild-caught impala ( Aepyceros melampus ). Ten adult female impala were induced with two induction protocols: one consisted of 0.2 mg/kg medetomidine, 4 mg/kg ketamine, and 0.15 mg/kg butorphanol (MKB) and one consisted of 0.375 mg/kg etorphine, 0.2 mg/kg medetomidine, and 0.2 mg/kg midazolam (EMM). In both treatments, anesthesia was maintained with a continuous intravenous infusion (CII) at an initial dose rate of 1...
March 2017: Journal of Zoo and Wildlife Medicine: Official Publication of the American Association of Zoo Veterinarians
https://www.readbyqxmd.com/read/28359862/ketamine-augmentation-of-electroconvulsive-therapy-to-improve-neuropsychological-and-clinical-outcomes-in-depression-ketamine-ect-a-multicentre-double-blind-randomised-parallel-group-superiority-trial
#20
Ian M Anderson, Andrew Blamire, Tim Branton, Ross Clark, Darragh Downey, Graham Dunn, Andrew Easton, Rebecca Elliott, Clare Elwell, Katherine Hayden, Fiona Holland, Salman Karim, Colleen Loo, Jo Lowe, Rajesh Nair, Timothy Oakley, Antony Prakash, Parveen K Sharma, Stephen R Williams, R Hamish McAllister-Williams
BACKGROUND: The use of electroconvulsive therapy (ECT) is limited by concerns about its cognitive adverse effects. Preliminary evidence suggests that administering the glutamate antagonist ketamine with ECT might alleviate cognitive adverse effects and accelerate symptomatic improvement; we tested this in a randomised trial of low-dose ketamine. METHODS: In this multicentre, randomised, parallel-group study in 11 ECT suites serving inpatient and outpatient care settings in seven National Health Service trusts in the North of England, we recruited severely depressed patients, who were diagnosed as having unipolar or bipolar depressive episodes defined as moderate or severe by DSM-IV criteria, aged at least 18 years, and were able and willing to provide written consent to participate in the study...
March 27, 2017: Lancet Psychiatry
keyword
keyword
28799
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"